Celcuity Stock Hits All-Time High On Gedatolisib Progress

Celcuity Inc. (CELC) shares reached an all-time high of $53.85, extending significant gains driven by positive developments for its lead drug candidate, Gedatolisib, targeting HR+/HER2- advanced breast cancer. The stock previously surged over 230% on July 28, 2025, following positive topline results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial, which demonstrated an unprecedented reduction in disease progression risk. Investor focus is now on the anticipated topline data from the PIK3CA mutant cohort by year-end 2025 and the ongoing VIKTORIA-2 trial, underscoring continued clinical momentum and market optimism.

Analysis

Celcuity Inc. (CELC) shares achieved a new all-time high of $53.85, a rally fundamentally driven by significant clinical progress with its lead drug candidate, Gedatolisib, a pan-PI3K and mTORC1/2 inhibitor for HR+/HER2- advanced breast cancer. The stock's valuation was materially re-rated on July 28, 2025, when it surged over 230% after the company announced positive topline results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial. These results were particularly impactful, reportedly showing an "unprecedented reduction in risk of disease progression or death." Investor focus is now directed towards the next major catalyst: the data readout from the trial's PIK3CA mutant cohort, anticipated by the end of 2025. Further bolstering the pipeline's potential, Celcuity has initiated a second Phase III study, VIKTORIA-2, evaluating Gedatolisib in a first-line treatment setting, indicating a broader strategic ambition beyond the initial patient population.

Key Decisions for Investors

• The primary near-term catalyst is the topline data from the VIKTORIA-1 trial's PIK3CA mutant cohort expected by year-end 2025, which represents a significant binary event for the stock.
• Given the stock's greater than 300% appreciation since December 2024, investors should recognize that substantial clinical success is already priced in, warranting caution around new entry points and consideration for trimming positions to manage risk.
• The initiation of the VIKTORIA-2 trial for a first-line indication expands the drug's long-term commercial potential, and its progress should be monitored as a key driver of future value beyond the current VIKTORIA-1 focus.